Skip to content

Ehlers-Danlos Syndrome Reference

The Ehlers–Danlos syndromes (EDS) were a group of heritable connective-tissue disorders whose features included joint hypermobility, tissue fragility, and skin or vascular findings in different combinations. The thirteen subtypes in the 2017 international classification had distinct diagnostic criteria and substantially different risks. Hypermobile Ehlers–Danlos syndrome (hEDS) was the most frequently encountered subtype, but it did not have an identified diagnostic genetic variant as of 2026.

Terminology and Classification

The 2017 international classification recognized thirteen EDS subtypes. Most were associated with pathogenic variants affecting collagen or other parts of the extracellular matrix and could be confirmed through molecular testing when the clinical presentation supported that subtype. hEDS remained the exception: diagnosis relied on clinical criteria and exclusion of other explanations.

Hypermobility spectrum disorders (HSD) described symptomatic joint hypermobility that did not meet criteria for hEDS or another condition that better explained the presentation. HSD was not an EDS subtype and did not mean that a person’s pain, instability, fatigue, or disability was trivial. hEDS and HSD could require similar symptom management even though their diagnostic classifications differed.

Older records sometimes used ‘’EDS type III’‘, ‘’joint hypermobility syndrome’‘, or ‘’benign joint hypermobility syndrome’‘. Those terms did not map perfectly onto the 2017 hEDS and HSD categories. Historical diagnoses therefore required interpretation in the context of the criteria and terminology used at the time.

Causes and Inheritance

EDS arose from inherited differences in connective tissue. The affected genes and inheritance patterns varied across subtypes. A person could have no known family diagnosis because of a new pathogenic variant, unrecognized relatives, limited family information, or variable expression.

No single causative gene had been established for hEDS as of 2026. The absence of a positive genetic test therefore did not exclude hEDS, while a broad consumer or connective-tissue panel could not confirm it. Conversely, generalized hypermobility alone did not establish hEDS.

Symptoms and Presentation

Presentation varied by subtype and individual. In hEDS, documented features included generalized joint hypermobility, joint instability, recurrent sprains, subluxations or dislocations, soft-tissue injuries, and chronic musculoskeletal pain. Some people had soft or mildly hyperextensible skin, easy bruising, or atrophic scars, but the pronounced skin fragility of classical EDS and the arterial or organ fragility of vascular EDS were not interchangeable with hEDS.

Muscles could work harder to stabilize lax joints, contributing to pain and fatigue. Fine-motor tasks, prolonged positioning, walking, standing, lifting, and repetitive activity could increase symptoms. A person might be able to move a joint through an unusually large range while still lacking stability, proprioceptive control, or pain-free function.

Migraine, orthostatic intolerance, functional gastrointestinal disorders, fatigue, sleep disturbance, and autonomic symptoms were reported more often in hEDS populations. These conditions still required their own assessment. Their coexistence did not prove that hEDS caused every symptom or that every person with hEDS had the same multisystem pattern.

Other EDS subtypes had different defining risks. Vascular EDS could involve life-threatening arterial or hollow-organ rupture. Classical EDS placed greater emphasis on skin hyperextensibility and atrophic scarring. Severe vascular events, marked skin fragility, unexplained organ rupture, or a concerning family history required subtype-specific genetic evaluation rather than assumption that the presentation was hEDS.

Diagnosis and Differential Diagnosis

The 2017 adult hEDS criteria required all three of the following:

  • generalized joint hypermobility, assessed with an age-adjusted Beighton score and relevant history when current movement no longer showed earlier flexibility;
  • at least two groups of additional findings involving systemic connective-tissue features, family history, or musculoskeletal complications; and
  • exclusion of unusual skin fragility, other heritable or acquired connective-tissue disorders, and alternative causes of joint hypermobility.

The Beighton score sampled a limited set of joints and did not measure pain, instability, or disability. Injury, surgery, age, muscle tightness, and changed mobility could reduce a person’s current score. Clinicians therefore considered history and the complete presentation rather than using one number as a stand-alone diagnosis.

For children and biologically immature adolescents, the 2023 pediatric framework classified generalized joint hypermobility according to musculoskeletal complications, skin or tissue findings, and comorbidities. Children were monitored and reevaluated as features evolved; adult hEDS criteria were applied after biological maturity. This reduced pressure to assign a lifelong adult label before the phenotype was clear while preserving access to care for symptomatic hypermobility.

Differential diagnosis included other EDS subtypes, HSD, Marfan syndrome, Loeys–Dietz syndrome, skeletal dysplasias, neuromuscular disorders, inflammatory or autoimmune disease, and acquired causes of joint laxity. Molecular testing was used when the history or examination suggested a genetically defined disorder. hEDS itself remained a clinical diagnosis.

Treatment and Management

No treatment corrected the underlying connective-tissue difference. Management focused on function, injury reduction, pain, and associated conditions.

Physical therapy was individualized around strength, proprioception, movement control, and joint stability. Exercise evidence remained limited, but rehabilitation could improve pain, function, and confidence for some people. Programs progressed according to tolerance and avoided repeatedly forcing unstable joints into end-range positions. Stretching was neither a universal treatment nor universally prohibited; its safety depended on the joint, the person’s control, and the purpose of the movement.

Occupational therapy, ergonomic changes, pacing, and task modification reduced repetitive strain. Braces, compression garments, tape, finger or wrist splints, and orthoses could improve stability or function when selected and fitted for the individual. Mobility aids could conserve energy, reduce falls, and permit participation without implying that the person could never walk.

Pain management could include rehabilitation, heat or cold, topical treatment, medication, psychological support for coping, and specialist care. New severe pain or loss of function still required evaluation for fracture, dislocation, neurological injury, or another acute cause rather than automatic attribution to EDS.

Management of POTS, gastrointestinal dysmotility, migraine, sleep disorders, ME/CFS, or mast-cell disease followed the evidence and diagnostic criteria for those conditions. Community discussion often grouped hEDS, POTS, and mast cell activation syndrome as a “triad,” but published reviews had not established a single shared mechanism or a universal three-condition syndrome. Symptom overlap did not substitute for diagnosis.

Course and Accessibility

EDS and HSD were lifelong, but function could fluctuate with injury, illness, hormonal changes, sleep, activity, pain, deconditioning, rehabilitation, and environment. A person’s support needs could change without the underlying condition becoming newly real or previously absent.

Useful access could include seating, permission to change position, reduced lifting or repetitive work, rest periods, ergonomic tools, temperature management, accessible transportation, flexible scheduling, braces or splints, and mobility equipment. Some people required assistance during an acute subluxation, pain flare, or fatigue episode while remaining independent in other parts of life.

Historical Context and Medical Evolution

Edvard Ehlers described patients with joint laxity and skin findings in 1901, and Henri-Alexandre Danlos added a further description in 1908. Later classification systems shifted from broad clinical groupings toward subtype-specific clinical and molecular criteria.

The Villefranche classification of 1997 recognized six major types. The 2017 international classification expanded the system to thirteen subtypes, separated hEDS from genetically defined types, and introduced the HSD framework for other symptomatic hypermobility presentations. The 2023 pediatric framework provided age-appropriate classification before biological maturity. These changes affected how older records and delayed diagnoses were interpreted.

Associated Characters

Charlie Rivera

Main article: Charlie Rivera

Charlie had hypermobile Ehlers–Danlos syndrome. His diagnosis followed the POTS and gastroparesis diagnoses made during his 2027 hospitalization, after a physician familiar with symptomatic hypermobility evaluated his joint history and current presentation.

His hEDS included chronic joint and muscle pain, unstable shoulders, hyperextending knees and fingers, back pain, recurrent sprains, and muscles that overworked to stabilize his joints. He described a manageable pain day as approximately three to four out of ten and a bad day as seven to eight. In his twenties and thirties, hEDS-related instability and soft-tissue vulnerability increased the consequences of falls, while undernutrition and low weight compromised bone health and POTS and vestibular dysfunction increased the likelihood of falling. hEDS was not treated as the sole cause of his fractures.

After a therapy appointment and an UberWAV ride left him severely nauseated, Charlie dry-heaved over the bathroom sink at home and subluxed his jaw. Logan Weston heard the click and whimper, asked permission to look, applied a cold pack, and supported Charlie until the pressure eased and the joint settled. The episode showed how an ordinary symptom from one condition could place an unstable joint under sudden strain.

Charlie later developed mast cell activation syndrome. MCAS affected his care as its own condition; its coexistence with hEDS, POTS, gastroparesis, and ME/CFS did not establish that any one of those diagnoses caused the others.

Alastair Hargreaves

Main article: Alastair Hargreaves

Alastair lived with hEDS-related joint instability, recurrent injuries, chronic pain, fatigue, migraines, and easy bruising. hEDS remained suspected and undiagnosed during his February 2011 collapse and hospitalization, and he received a formal diagnosis later. Osteoporosis separately increased his fracture risk. He used a wheelchair as needed for pain, fatigue, mobility, crowds, and injury prevention.

Dr. Ren Adler

Main article: Dr. Ren Adler

Ren lived with Ehlers–Danlos syndrome and chronic joint instability. Burnout and the physical demands of emergency-room nursing led her to leave direct patient care. She used compression gloves, physical pacing, and structured work systems while serving as clinical operations coordinator for Logan Weston.

Medical-System Interactions

Joint hypermobility was often treated as harmless flexibility even when a patient reported pain, instability, or repeated injury. Fragmented care could separate musculoskeletal, autonomic, gastrointestinal, pain, and fatigue symptoms among different specialties without assessing how they interacted. The lack of a molecular test for hEDS also created opportunities for both dismissal and overdiagnosis.

Care required two distinctions at once: a normal genetic panel did not rule out hEDS, and symptom overlap did not confirm it. Clinicians still had to apply the clinical criteria, assess alternative diagnoses, investigate acute injuries, and avoid assigning every symptom to connective tissue.

Public and Community Context

People with EDS and HSD used disability communities, patient organizations, and online networks to share access strategies and locate clinicians familiar with symptomatic hypermobility. Those networks increased recognition of patterns that had been missed in fragmented care. They also circulated shorthand, proposed associations, and treatment claims whose evidentiary support varied. Lived experience could identify questions that deserved investigation without making every community pattern a settled clinical fact.

Sources

Medical Conditions Chronic Conditions